Amitriptyline Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	1-2 mg/kg	q12h (every 12 hours)	Duration: 2-4 weeks for behavioral effects; may be long-term Notes: Start at lower end and titrate gradually. Administer with food to reduce GI upset. Monitor for sedation and anticholinergic effects.
Cat	PO	5-10 mg per cat (approximately 0.5-1 mg/kg)	q24h (once daily, usually in the evening)	Duration: 2-4 weeks for behavioral effects; may be long-term Notes: Use lower doses initially. Sedation is common; give at night. Monitor for urine retention and constipation.
Horse	PO	0.5-1 mg/kg	q12h	Duration: Not well established; use with caution Notes: Limited data; not routinely recommended. May cause colic or CNS excitation.
Rabbit	PO	5-10 mg/kg	q24h	Duration: Not well established Notes: Use with caution; may cause GI stasis. Monitor for reduced appetite.

Clinical Indications & Species Uses

General Indications

Behavioral disorders (anxiety, phobias, compulsive behaviors)
Chronic pain management (adjunctive)
Pruritus (adjunctive)

Dog (Canine)

Separation anxiety
Generalized anxiety disorders
Obsessive-compulsive disorders (e.g., flank sucking, tail chasing)
Chronic pain (adjunctive therapy, especially neuropathic pain)
Pruritus (as an adjunct due to antihistaminic effects)

Cat (Feline)

Urine spraying (feline idiopathic cystitis-associated)
Anxiety-related behavioral disorders (e.g., fear, phobias)
Chronic interstitial cystitis (adjunctive therapy)
Psychogenic alopecia (overgrooming)

Rabbit & Small Mammals

Occasionally used for behavioral issues (e.g., anxiety, aggression) but safety and efficacy are not well established.

Exotic & Other Species

Occasionally used in small mammals (e.g., ferrets, rodents) for behavioral disorders, but evidence is anecdotal.

Pharmacology & Mechanism of Action

Drug Class: Tricyclic Antidepressant (TCA) | Pharmacological Group: Dibenzocycloheptene derivative; Serotonin and Norepinephrine Reuptake Inhibitor (SNRI-like)

Mechanism of Action: Amitriptyline primarily inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) at presynaptic neuronal membranes in the central nervous system, increasing their concentrations in the synaptic cleft. It also blocks histaminergic (H1), muscarinic cholinergic, and alpha-1 adrenergic receptors, contributing to its sedative, anticholinergic, and hypotensive effects. Chronic administration leads to downregulation of beta-adrenergic and serotonin receptors, which may underlie its therapeutic effects in behavioral disorders. In veterinary medicine, it is used for its anxiolytic, antidepressant, and analgesic (in neuropathic pain) properties.

Pharmacodynamics: Amitriptyline exhibits a broad range of pharmacodynamic actions: it inhibits serotonin and norepinephrine reuptake, leading to enhanced monoaminergic neurotransmission. It also antagonizes H1 receptors (sedation, weight gain), muscarinic receptors (dry mouth, urinary retention, tachycardia), and alpha-1 adrenergic receptors (orthostatic hypotension, dizziness). In animals, it has been shown to reduce anxiety-related behaviors, decrease urine spraying in cats, and provide analgesia in chronic pain conditions. Its antihistaminic effects may also be beneficial in pruritic conditions. The onset of therapeutic effect is typically 2-4 weeks.

⚡ Pharmacokinetics Summary

Absorption: Amitriptyline is well absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations occur approximately 2-4 hours after dosing in dogs and cats. Food may delay absorption but not the extent. Bioavailability is variable due to extensive first-pass metabolism.

Distribution: Amitriptyline is highly lipophilic and extensively distributed throughout the body, with a large volume of distribution. It crosses the blood-brain barrier and placenta and is excreted in milk. It is highly protein-bound (approximately 90-95%) in plasma.

Metabolism: Amitriptyline undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes (CYP2D6, CYP3A4, CYP2C19) to its active metabolite nortriptyline, which is also a potent norepinephrine reuptake inhibitor. Further metabolism produces hydroxylated and conjugated metabolites. In animals, the metabolic pathways are similar, but species differences exist in the rate and extent of metabolism.

Excretion: Metabolites are primarily excreted in the urine (as glucuronide and sulfate conjugates) and, to a lesser extent, in feces. Only a small fraction is excreted unchanged. In dogs, the elimination half-life is approximately 12-24 hours; in cats, it is longer, around 24-48 hours.

Half-Life: Dog: 12-24 hours; Cat: 24-48 hours; Horse: approximately 6-8 hours (limited data)

Bioavailability: Oral bioavailability is variable (30-60%) due to first-pass metabolism; in dogs, it is approximately 50%.

Protein Binding: Approximately 90-95% in plasma

Available Formulations & Strengths

Oral Tablet 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg (PO)

Oral Capsule 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg (PO)

Oral Solution 10 mg/mL (compounded) (PO)

Injectable Solution (not commonly used in veterinary medicine) 10 mg/mL (for human use; not approved for animals) (IM/IV (not recommended))

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to amitriptyline or other tricyclic antidepressants
Concurrent use with monoamine oxidase inhibitors (MAOIs) - risk of serotonin syndrome
Recent myocardial infarction or cardiac conduction abnormalities (e.g., arrhythmias)
Severe hepatic disease
Narrow-angle glaucoma
Urinary retention (e.g., due to prostatic hyperplasia or urethral obstruction)
Pregnancy and lactation (unless benefits outweigh risks; use with caution)

Warnings & Clinical Precautions:

Use with caution in animals with cardiovascular disease, seizure disorders, or thyroid dysfunction.
May cause sedation; caution when used in working animals or those requiring alertness.
Anticholinergic effects may exacerbate constipation, urinary retention, or dry mouth.
In cats, may cause significant sedation and behavioral changes; monitor closely.
Do not discontinue abruptly; taper dose to avoid withdrawal symptoms.
Use with caution in geriatric animals due to increased sensitivity to anticholinergic effects.
In food animals, extra-label use is prohibited; withdrawal times must be observed if used off-label.

Adverse Effects & Reactions

Common:

Sedation
Dry mouth
Constipation
Urinary retention
Increased appetite and weight gain
Mydriasis (pupil dilation)
Tachycardia

Serious / Severe:

Cardiac arrhythmias (e.g., QT prolongation, ventricular arrhythmias)
Seizures
Hepatotoxicity
Serotonin syndrome (when combined with other serotonergic drugs)
Hypotension
Bone marrow suppression (rare)

Rare:

Paradoxical aggression or excitation
Ataxia
Tremors
Photosensitivity
Blood dyscrasias (e.g., agranulocytosis)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Monoamine oxidase inhibitors (MAOIs) e.g., selegiline	Risk of serotonin syndrome (hyperthermia, agitation, tremors, seizures). Contraindicated.	High
Other serotonergic drugs (e.g., SSRIs, SNRIs, tramadol)	Additive serotonergic effects, risk of serotonin syndrome.	High
Anticholinergic agents (e.g., atropine, antihistamines)	Additive anticholinergic effects (dry mouth, constipation, urinary retention).	Moderate
CNS depressants (e.g., barbiturates, benzodiazepines, opioids)	Additive sedation and respiratory depression.	Moderate
Sympathomimetics (e.g., epinephrine, phenylpropanolamine)	Increased risk of cardiac arrhythmias and hypertension.	Moderate
Cimetidine, fluoxetine, or other CYP inhibitors	May increase amitriptyline plasma levels, increasing toxicity risk.	Moderate
Thyroid hormones	May increase risk of cardiac arrhythmias.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe sedation or coma
Cardiac arrhythmias (e.g., tachycardia, QT prolongation, ventricular fibrillation)
Hypotension or hypertension
Seizures
Respiratory depression
Anticholinergic crisis (hyperthermia, mydriasis, ileus, urinary retention)

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and animal is conscious (do not induce if CNS depression). Administer activated charcoal to reduce absorption. Provide intravenous fluids for hypotension. Monitor ECG continuously; treat arrhythmias with sodium bicarbonate (for QRS widening) and lidocaine for ventricular arrhythmias. Control seizures with diazepam or barbiturates. Avoid physostigmine unless severe anticholinergic signs are life-threatening. Provide respiratory support as needed. Hospitalization and intensive care are required.

Food Animal Withdrawal Times

Amitriptyline is not approved for use in food animals. Extra-label use in food animals is prohibited under AMDUCA due to lack of established withdrawal times. If used off-label, a prolonged withdrawal period (e.g., 30 days for meat and 7 days for milk) may be considered, but it is not recommended.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in a tightly closed container. Compounded oral solutions should be stored according to the compounding pharmacy's instructions, often refrigerated.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not approved for veterinary use; approved for human use in the US. No veterinary-approved formulations exist.

Extra-Label (Off-Label) Use: In the US, amitriptyline is not FDA-approved for veterinary use; it is used extra-label under the Animal Medicinal Drug Use Clarification Act (AMDUCA). Extra-label use is permitted in non-food animals by or on the order of a licensed veterinarian within a valid VCPR. Use in food animals is prohibited.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Amitriptyline is a tricyclic antidepressant used in veterinary medicine primarily for behavioral disorders such as separation anxiety, generalized anxiety, and compulsive behaviors in dogs and cats. It is also used as an adjunctive therapy for chronic pain, particularly neuropathic pain, and for feline interstitial cystitis. Its anticholinergic and antihistaminic properties can be beneficial in pruritic conditions but also lead to common side effects like sedation, dry mouth, and constipation. Clinical response may take 2-4 weeks, so patience is required. Doses should be individualized, starting low and titrating upward. Monitoring for cardiac effects is important, especially in animals with pre-existing heart disease. Avoid concurrent use with MAOIs and other serotonergic drugs. In cats, once-daily dosing is often sufficient due to a longer half-life. Abrupt discontinuation should be avoided. Due to lack of safety data, use in food animals is not recommended. Always consider a thorough behavioral assessment and environmental modification in conjunction with pharmacotherapy.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)